Evaluation of the Protective Effect of Empagliflozin on Doxorubicin- induced Cardiotoxicity in Breast Cancer patients; A Randomized Clinical Trial

Inclusion criteria:

Patients with newly diagnosed breast cancer, stage 1 to 3, who are candidates for a chemotherapy regimen containing doxorubicin. Reading and signing the informed consent form to participate in the clinical trial People over the age of 18. People who are able to consume food. Negative pregnancy test in women of childbearing age

Exclusion criteria:

A history of cancer in the past that has received cardiotoxic drugs such as doxorubicin History of chest radiotherapy LVEF less than 50% before starting treatment Being treated for heart failure and taking medications to treat heart failure History of congenital heart disease or history of coronary artery disease History of more than moderate valvular heart disease based on history and records History of hypertension or history of symptomatic hypotension or SBP less than 100 on the first or second visit History of atrial fibrillation History of cardiomyopathy and use of heart failure medications based on the medical history in the file History of stroke Cognitive and neurological disorders Simultaneous participation in another clinical trial Allergy to any of the materials used in the trial Liver disease or LFTs greater than 3 times ULN at first visit Kidney failure in the form of a GFR less than 30 or requiring dialysis, diagnosed at the first visit History of diabetic ketoacidosis History of surgery on the gastrointestinal tract or a gastrointestinal disorder that interferes with drug absorption Patients who have used SGLT2I drugs for at least 3 months before referral Alcohol or drug abuse

Target sample size: 152